Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer

(2023) Jia‐Yi Lin et al.   Small

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway

(2023) Kun Wang et al.   Advanced Science

Antibody‐Incorporated Nanomedicines for Cancer Therapy

(2022) Shun‐Yu Wu et al.   ADVANCED MATERIALS

PROTAC targeted protein degraders: the past is prologue

(2022) Miklós Békés et al.   NATURE REVIEWS DRUG DISCOVERY

Enzyme‐Engineered Conjugated Polymer Nanoplatform for Activatable Companion Diagnostics and Multistage Augmented Synergistic Therapy

(2022) Jiayingzi Wu et al.   ADVANCED MATERIALS

Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers

(2022) Jinfeng Yu et al.   Frontiers in Molecular Biosciences

Semiconducting Polymer Nanoparticles with Surface‐Mimicking Protein Secondary Structure as Lysosome‐Targeting Chimaeras for Self‐Synergistic Cancer Immunotherapy

(2022) Ji Qi et al.   ADVANCED MATERIALS

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

(2021) Green Ahn et al.   Nature Chemical Biology

ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation

(2021) Chia-Hsing Shen et al.   Frontiers in Cell and Developmental Biology

Antibody‐Drug‐Conjugate Therapy for Hematological Cancers: Matching Cell Biology with Clinical Benefit

(2021) Michael A. Firer et al.   ADVANCED FUNCTIONAL MATERIALS

Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation

(2020) Sylwia Jones et al.   Scientific Reports

Lysosome-targeting chimaeras for degradation of extracellular proteins

(2020) Steven M. Banik et al.   NATURE

Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug

(2020) Han Young Kim et al.   JOURNAL OF CONTROLLED RELEASE

Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab

(2018) Huanrong Ma et al.   INTERNATIONAL JOURNAL OF CANCER

EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer

(2017) Yasuyuki Okada et al.   MOLECULAR CANCER RESEARCH

Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging

(2016) Man Kyu Shim et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

(2016) Kanak Raina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cloning and Expression of a Novel Target Fusion Protein and its Application in Anti-Tumor Therapy

(2015) Rui Sun et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth

(2015) J. Mendelsohn et al.   CLINICAL CANCER RESEARCH

In vivo fluorescence imaging for cancer diagnosis using receptor-targeted epidermal growth factor-based nanoprobe

(2013) Ju Hee Ryu et al.   BIOMATERIALS

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

(2010) M. W. Pedersen et al.   CANCER RESEARCH

The effect of bafilomycin A1 and protease inhibitors on the degradation and recycling of a Class 5-mutant LDLR

(2009) K. Tveten et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

An A13 Repeat within the 3'-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression

(2009) Z. Yuan et al.   CANCER RESEARCH

Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor

(2009) H.-J. Liao et al.   CANCER RESEARCH

Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer

(2009) C. Shah et al.   CLINICAL CANCER RESEARCH

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY